On July 3, Alebund Pharmaceuticals-B (09637.HK) rose 7.92% in regular trading, trading at 28.74 HKD/share, with turnover of approximately 4.98 million HKD.

Alebund Pharmaceuticals listed on the Hong Kong Stock Exchange on June 29 at an offering price of 22.60 HKD/share, closing up 103.54% on its debut at 46.00 HKD. The stock subsequently experienced a sharp correction, falling 21.6% on July 2 to approach its IPO price level, before today's rebound.

Alebund Pharmaceuticals is a biopharmaceutical company focused on kidney disease therapies, founded in 2018. The company possesses a diversified pipeline covering chronic kidney disease complications, IgA nephropathy, diabetic kidney disease, and other indications. Its core product AP301 is an oral phosphate binder for hyperphosphatemia treatment that has completed China Phase III registration trials and is expected to file for NDA approval in the near term, while advancing a global Phase III pivotal multi-center clinical trial in the US and China.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)